Garland Moeller, MD
Rheumatology · Havelock, NCNPI 1912990334
Payments from drug & device makers
Across 687 payments — averaging $94.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Janssen Scientific Affairs, LLC$40K
- Johnson & Johnson$13K
- Amgen$3K
- AbbVie$2K
- Pfizer$2K
- Lilly USA, LLC$1K
- plus $4K from 27 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Janssen Scientific Affairs, LLC | 38 | $40,387 |
| Johnson & Johnson | 38 | $12,581 |
| Amgen(2 entities) | 125 | $2,563 |
| AbbVie | 76 | $1,924 |
| Pfizer | 133 | $1,686 |
| Lilly USA, LLC | 86 | $1,408 |
| Novartis | 46 | $1,164 |
| GSK | 29 | $679 |
| AstraZeneca(2 entities) | 15 | $356 |
| Regeneron Healthcare Solutions, Inc. | 13 | $330 |
| Aurinia Pharma U.S., Inc. | 15 | $265 |
| Novo Nordisk | 13 | $217 |
| Bristol Myers Squibb | 6 | $183 |
| Sanofi | 3 | $152 |
| Genentech USA, Inc. | 10 | $152 |
| UCB, Inc. | 5 | $148 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $142 |
| Fresenius Kabi USA, LLC | 5 | $138 |
| Actelion Pharmaceuticals US, Inc. | 1 | $102 |
| Boehringer Ingelheim | 4 | $67 |
| Daiichi Sankyo Inc. | 3 | $53 |
| E.r. Squibb & Sons, L.L.C. | 4 | $53 |
| Bayer | 2 | $48 |
| Radius Health, Inc. | 2 | $41 |
| Merck | 2 | $31 |
| Abbott | 1 | $24 |
| Phathom Pharmaceuticals, Inc. | 1 | $23 |
| ANI Pharmaceuticals, Inc. | 1 | $22 |
| Mallinckrodt Hospital Products Inc. | 1 | $20 |
| Astellas Pharma US Inc | 1 | $17 |
| Exact Sciences | 1 | $14 |
| Boston Scientific | 1 | $13 |
| Medexus Pharma, Inc. | 1 | $13 |
How this compares
$65,017 in reported general payments places this provider in the 80th percentile of 210 rheumatology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other rheumatology in Havelock
- Laura SchanbergDurham$6.9M
- Rakesh PatelSalisbury$4M
- Jane BoxCharlotte$3.9M
- Gordon LamCharlotte$3.5M
- David SnowDelco$3.4M
- Alireza NamiCharlotte$3.1M
- Tauseef SyedGreensboro$1.7M
- Michael HershfieldDurham$1.5M
- Ralph SnydermanDurham$1.3M
- Megan ClowseDurham$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.